Pimobendan 74150-27-9 Metabolism PDE inhibitor
Uku:T/T, L/C
Kumu Huahana:Kina
Awa moku:Pekina/Shanghai/Hangzhou
Kauoha (MOQ):1g
Ka manawa o waena o ka hoʻomaka a i ka wā pau:3 lā hana
Hiki ke hana:1kg / mahina
Kūlana mālama:Hoʻopaʻa ʻia ma kahi anuanu, maloʻo, ka lumi wela.
Mea paʻa:hue, ʻōmole
Nui pūʻolo:1g/puʻu, 5/puʻu, 10g/puʻu, 50g/puʻu, 500g/puʻu
ʻIke palekana:UN 2811 6.1/PG 3
Hoʻolauna
ʻO Pimobendan, he lāʻau lapaʻau holoholona.He mea hoʻomaʻamaʻa calcium a me kahi mea hoʻopale koho o phosphodiesterase 3 (PDE3) me nā hopena inotropic a me nā vasodilator maikaʻi.
Hoʻohana ʻia ʻo Pimobendan i ka mālama ʻana i ka hōʻeha ʻana o ka naʻau i nā ʻīlio, ka mea maʻamau i ka maʻi myxomatous mitral valve (kahi i ʻike mua ʻia ʻo endocardiosis), a i ʻole ka cardiomyopathy dilated.Ua hōʻike ʻia ka noiʻi ma ke ʻano he monotherapy, hoʻonui ka pimobendan i ka manawa ola a hoʻomaikaʻi i ka maikaʻi o ke ola i nā poʻe maʻi canine me ka puʻuwai congestive lua i ka maʻi valve mitral ke hoʻohālikelike ʻia me benazepril, kahi mea hoʻopaneʻe ACE.
Hōʻike (USP43)
| 'ikamu | Hōʻike |
| Ka nana aku | ʻO ka pauka keʻokeʻo a melemele iki paha, hygroscopic |
| Mp | Ma kahi o 242 ℃ |
| Ka hoʻoheheʻe | ʻAʻole hiki ke hoʻoheheʻe ʻia i ka wai, hiki ke hoʻoheheʻe ʻia i ka dimethylformamide, hiki ke hoʻoheheʻe ʻia i ka acetone a me ka methanil. |
| ʻIkepili | Infrared absorption spectrophotometry, Hoʻohālikelike pimobendan CRS. |
| ʻO ka manawa paʻa o ke kiʻekiʻe nui o ka Sample solution e like me ka mea o ka solution stock Standard, e like me ka loaʻa ʻana ma ka hōʻike Organic Impurities. | |
| Nā metala kaumaha | ≤10ppm |
| Granularity | P90 ≤ 25μ m |
| Nui ʻāpana | 20-80 mesh |
| Nā mea hoʻoheheʻe koena | ≤ 500ppm |
| Wai | ≤ 1.0% |
| Hoʻāʻo | 98.0%~102.0% |
| Lehu sulphated | ≤ 0.10% |
| Nā mea pili (HPLC) | |
| haumia A | ≤ 0.10% |
| haumia B | ≤ 0.10% |
| ʻO nā mea haumia ʻē aʻe | ≤ 0.10% |
| Huina haumia | ≤ 0.20% |
